Italfarmaco and Multicare Pharma Sign Exclusive Distribution Deal for Givinostat (Duvyzat), a DMD Treatment in Brazil
Italfarmaco announced an exclusive agreement with Multicare Pharma, a prominent pharmaceutical company in Latin America. Multicare Pharma will support the regulatory approval in Brazil...
Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial
Avidity Biosciences announced positive new data from participants treated continuously with del-zota for one year in the EXPLORE44 and EXPLORE44-OLE trials. These data demonstrated...
Belief BioMed Announced Successful Completion of First Dose of BBM-D101 Gene Therapy
Belief BioMed, an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the registration clinical trial (CTR20252461) of its independently developed...
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Keros Therapeutics announced that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American...
SQY Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for Exon 51 Skipping Therapy SQY51 for Treatment of Duchenne Muscular Dystrophy
SQY51 had already obtained Orphan Drug Designation from the US Food and Drug Administration (FDA) in Duchenne Muscular Dystrophy in May 2024.SQY51 is a...